Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prabotulinum toxin A for facial lifting in adults
TCTR20261031012Phase 3Completed
- Sponsor
- St John's Institute of Dermatology
- Start
- Mar 2025
- Modality
- Bacterial Toxin Conjugates → Immunotoxins → Antibody Conjugates → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of prabotulinumtoxinA in facial ptosis and rhytides, sponsored by St John's Institute of Dermatology. Primary endpoint: Facial lifting at 16 weeks. Started Mar 2025; status: completed.
02
Drugs
prabotulinumtoxinA
03
Conditions
facial ptosisrhytides
Beyond the preview
Go deeper on TCTR20261031012.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20261031012.